---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000253"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T00:48:34.298551+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q4 net product rev $346M, FY $1.24B (+39%); FY24 guide $1.4-1.5B; HELIOS-B readout late June/early July

## Summary
- Q4 net product revenue $346M: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
- Full year 2023 net product revenue $1.24B, up 39% YoY; GAAP net loss per share ($3.52); non-GAAP ($1.61).
- FY24 guidance: combined net product revenue $1.4B-$1.5B, plus collaboration and royalty revenue; operating expense guidance provided.
- HELIOS-B Phase 3 top-line results expected late June or early July; updated statistical analysis plan announced.
- FDA cleared Part B of ALN-APP Phase 1 study at doses up to 180 mg every six months; partial clinical hold remains for higher doses.

## SEC filing metadata
- accession: 0001157523-24-000253
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/0001157523-24-000253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/a53896787.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000253
- JSON: https://secwatch.observer/filing/0001157523-24-000253.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000253.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue $346 Million and $1,241 Million, Respectively.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $346 Million and $1,241 Million, Respectively
  - Result: reported results
  source text: Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000115752324000253/0001157523-24-000253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.